TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $40.67 Average Price Target from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has been given a consensus rating of “Moderate Buy” by the six research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $40.67.

A number of research firms have recently issued reports on TGTX. JPMorgan Chase & Co. lifted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. TD Cowen initiated coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a report on Wednesday. Finally, The Goldman Sachs Group increased their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th.

Insider Buying and Selling at TG Therapeutics

In related news, Director Sagar Lonial sold 5,000 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sean A. Power sold 11,337 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares of the company’s stock, valued at $20,313,443.28. This trade represents a 1.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,358 shares of company stock worth $781,497 over the last 90 days. Company insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

A number of large investors have recently made changes to their positions in TGTX. Brookstone Capital Management boosted its stake in TG Therapeutics by 3.7% in the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 624 shares during the period. GAMMA Investing LLC boosted its position in shares of TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 2,171 shares during the period. JPMorgan Chase & Co. grew its stake in shares of TG Therapeutics by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after acquiring an additional 270,286 shares in the last quarter. Principal Financial Group Inc. increased its position in TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after acquiring an additional 725,371 shares during the period. Finally, Franklin Resources Inc. raised its stake in TG Therapeutics by 3.8% in the 3rd quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company’s stock worth $2,945,000 after purchasing an additional 4,756 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Down 3.4 %

NASDAQ TGTX opened at $29.14 on Tuesday. TG Therapeutics has a one year low of $12.84 and a one year high of $36.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market cap of $4.54 billion, a P/E ratio of -291.37 and a beta of 2.24. The stock’s 50-day moving average is $31.69 and its 200-day moving average is $25.63.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 EPS. Sell-side analysts anticipate that TG Therapeutics will post 0.07 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.